Oscar Boutros Lahoud MD

Hematologic Oncology

Deputy Chief Clinical Officer, NYU Perlmutter Cancer Center

5718 2nd Ave2nd FloorBrooklyn, NY 11220
Phone+1 646-754-8570
Fax+1 646-754-8501

Dr. Lahoud is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lahoud's full profile Already have an account?

Summary

Oscar Lahoud, MD, based in Brooklyn, NY, is a hematologist specialized in hematologic oncology. He pursued medical education at the University of Michigan and completed advanced fellowship training in bone marrow transplant and cellular therapy at Memorial Sloan Kettering Cancer Center. Currently, he holds several leadership roles at NYU Langone Hospital and Perlmutter Cancer Center, including Chief Medical Officer and Deputy Chief Clinical Officer. Previously, he served in various operational and strategic leadership capacities at Memorial Sloan Kettering Cancer Center. His expertise includes immunotherapy, hematologic oncology, stem cell transplantation, and cellular therapy. Dr. Lahoud has contributed to several publications on topics like multiple myeloma, lymphoma and CAR-T cell therapy, with his research appearing in reputable journals such as the Journal of Clinical Oncology, Lancet Oncology, JAMA Oncology, Cancer Discovery and Blood.

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Blood & Bone Marrow Transplant, 2016 - 2017
Maimonides Medical CenterFellowship, Hematology and Medical Oncology, 2013 - 2016
Maimonides Medical CenterResidency, Internal Medicine, 2009 - 2012
University of Michigan Medical SchoolClass of 2009

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 2012 - 2028
NJ State Medical License 2021 - 2025
CT State Medical License 2023 - 2024
NC State Medical License 2020 - 2022
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

CD8CD38T cells identify functional high-risk multiple myeloma after autologous transplant: BMT CTN 0702 correlates.
Nezar Mehanna, Andriy Derkach, Billel Gasmi, Theodora Anagnostou, Heather J Landau
Blood Neoplasia. 2026-08-01
A pilot trial evaluating lenalidomide and oral azacitidine with radiotherapy for patients with newly diagnosed and relapsed plasmacytoma.
Urvi A Shah, Andriy Derkach, Meghana Pagadala, Kelly Barnett, Sean Devlin
Haematologica. 2026-07-23
Immunoglobulin replacement after chimeric antigen receptor T-cell therapy in large B-cell lymphoma with hypogammaglobulinaemia: Secondary Center for International Bloo...
Sarah Makhani, Thilan Tudor, Efrat Luttwak, Mohammad Alhomoud, Maher Abdul-Hay
British Journal of Haematology. 2026-07-22

Abstracts/Posters

A Phase 1/2 Study to Assess Safety and Dose of Ixazomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Patients with Light Chain (AL) Amyloi...
Oscar B Lahoud, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple My...
Oscar B Lahoud, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Ph...
Oscar B Lahoud, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m2) in Combination with...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Renowned Blood Cancer Expert Named NYU Langone Hospital—Brooklyn’s New Section Chief of HematologySeptember 9th, 2024
Memorial Sloan Kettering and New York Cancer and Blood Specialists Partner on New Flatbush Cancer Care CenterApril 5th, 2023
NYU Langone Health Leader Discusses Vision to Enhance Care & Make Life Easier for People with CancerApril 23rd, 2024